Neuro-Oncology Program

摘要-神经肿瘤学计划 根据美国国家癌症研究所2014年公布的数据，估计有162,341人 美国患有脑癌和其他神经系统癌症的人。恶性原发脑瘤 是儿童和年轻人中最常见的癌症死亡原因，占死亡人数的比例比 肾癌或黑色素瘤。 神经肿瘤学计划是杜克大学最著名和最古老的癌症计划之一，拥有 2017年庆祝成立80周年。杜克大学第一个建立脑瘤研究和临床活动 是1937年从约翰·霍普金斯大学来到杜克大学的巴恩斯·伍德霍尔博士。神经肿瘤学项目已经 自从#年首次被指定为NCI综合癌症中心以来，DCI一直是该中心的首要项目 1972年。 研究范围从最基础的科学到临床试验，涵盖了各种重点领域，包括 基础和功能基因组学；建立一个世界级的生物库，包括4000多名成年人和 儿童脑瘤样本、80多个异种移植和转基因模型重述人类疾病 用于药物/制剂筛选；为原发和转移性中枢神经系统肿瘤开发新的免疫疗法； 设计和执行I、II和III期临床试验；改善患者的生活质量和治疗 通过支持性护理临床试验以及分子流行病学和基因组研究获得的经验 恶性脑肿瘤的致病因素。这项研究是由神经肿瘤学项目的使命推动的 目的：确定成人和儿童所有主要类型恶性脑的病因和相关肿瘤生物标志物。 以及在创新和预测模型系统中从筛查中发明和转化新的治疗方法 在开创性的临床试验中进行人体测试和开发。全面性肿瘤的维护 下一代神经肿瘤学家的生物信息库和培训确保了 神经肿瘤学计划及其研究目标。 该计划由27名主要成员和6名次要成员组成，范围广泛，共有8名成员 杜克大学内有不同的系和1所学校和研究所。小学教育的直接资助总额 该计划的成员费用为1190万美元，其中610万美元接受同行审查，其中370万美元来自NCI。从2014年到2018年， 项目成员在PubMed引用的同行评议期刊上发表了415篇论文。在这些出版物中，33% 是方案内协作的结果，36%是方案间协作的结果。在.期间 在当前的授权期间，该计划招募了948名受试者参加所有试验，736名受试者参加干预试验，551名受试者参加 治疗试验。

ABSTRACT – NEURO-ONCOLOGY PROGRAM According to data published by the National Cancer Institute in 2014, there were an estimated 162,341 people living with brain and other nervous system cancer in the United States. Malignant primary brain tumors are the most frequent cause of cancer death in children and young adults and account for more deaths than cancer of the kidney or melanoma. The Neuro-Oncology Program is one of the most well-known and oldest cancer programs at Duke, having celebrated its 80th anniversary in 2017. The first to establish brain tumor research and clinical activities at Duke was Dr. Barnes Woodhall, who came to Duke from Johns Hopkins in 1937. The Neuro-Oncology Program has been a premier program within the DCI since its initial designation as an NCI Comprehensive Cancer Center in 1972. Research ranges from the most basic science to clinical trials encompassing various focus areas including basic and functional genomics; establishment of a world class biorepository including more than 4000 adult and pediatric brain tumor samples, more than 80 xenografts and transgenic models to recapitulate human disease and for drug/agent screening; development of novel immunotherapies for primary and metastatic CNS tumors; design and execution of Phase I, II, and III clinical trials; improving patient’s quality of life and treatment experience through Supportive Care clinical trials; and molecular epidemiology and genomic studies to identify causation factors of malignant brain tumors. This research is driven by the Neuro-Oncology Program’s mission to identify the cause and relevant tumor biomarkers in all major types of adult and childhood malignant brain tumors and to invent and translate novel therapeutics from screening in innovative and predictive model systems to human testing and development in pioneering clinical trials. Maintenance of the comprehensive tumor biorepository and training of the next generation of neuro-oncologists ensures the continuing development of the Neuro-Oncology Program and its research goals. The Program is comprised of 27 primary members and 6 secondary members from a wide spectrum of 8 different departments and 1 school and institutes within Duke University. Total direct funding for primary Program members is $11.9M of which $6.1M is peer reviewed, including $3.7M from the NCI. From 2014-2018, Program members published 415 papers in peer-reviewed journals cited in PubMed. Of these publications, 33% are the result of intra-programmatic collaborations and 36% are due to inter-programmatic collaborations. During the current grant period, the program enrolled 948 subjects to all trials, 736 to interventional trials, and 551 to treatment trials.